ETL and the Future of Data: A Deep Dive into Data Integration and Its Challenges

Data processing has grown beyond a mere pillar of corporate decision-making and strategic planning. As we embrace a wider range of data applications, data now trends as a topic capturing the widespread fascination of the public.

Therefore, we cannot simply overlook the instrumental role of a method known as ETL – Extract, Transform, Load, in the realm of data integration. By traditional interpretations, ETL refers to the cycle of data extraction, transformation, and loading.

ETL involves plucking data from diverse sources, transforming, and consolidating the data post-cleaning, and subsequently loading it into a target system like a data warehouse or data lake. Though it may sound like a foreign language, or seemingly far removed from our lives, ETL is indeed intertwined with our daily routines.

The utilization of ETL is broad, infiltrating all facets of our life from enterprise data integration and system creation, to data migration and amalgamation. In essence, enterprise data integration involves converging dispersed data within a company into a single, unified data warehouse or data lake to bolster decision-making and analysis. In sectors like business intelligence and report generation, we employ ETL to load data into the data warehouse, enabling further generation of reports, dashboards, and visual analyses using data analytics tools. Conventionally, during system upgrades, mergers, or data migrations, data migration and integration employ ETL to transfer data from the older systems to the new, ensuring data integrity and uniformity.

The International Data Corporation (IDC) forecasts a more-than-five-fold increase in global data volume, from 33 ZB in 2018 to 175 ZB by 2025. With this surge in data processing demands, myriad challenges have inevitably surfaced, most notably in data quality and security. For example, effective data processing is a substantial challenge for firms that rely heavily on data-intensive technology.

We contacted Xi Dai, a senior data integration engineer from The Weather Company, to help us better understand and counteract these concerns.

“Only through effective data integration and robust ETL processes can companies consolidate data from segmented and heterogeneous sources into a harmonious and credible data set,” Xi Dai opined.

Furthermore, Ralph Kimball, a pioneer in the data warehouse field, put forth a unique approach to using dimensional modeling for data warehouse design, otherwise known as “ETL architecture design”. Kimball underlined the centrality of the ETL process’s reliability, repeatability, and scalability in the integration of data warehouses.

Xi Dai disclosed during her interview that she applies Kimball’s principles of ETL architecture design in her daily work, extracting data to a temporary storage locale, and transforming and cleansing it before it is loaded into the data warehouse. She spoke highly of these practices that offer her a solution-oriented compass toward implementing data integration analysis within the enterprise.

Another critical worry for the data integration sector is data security. For many companies, the variety of data sources raises concerns about assuring accuracy, integrity, and consistency. For example, sales data may contain incomplete or duplicate sales records, resulting in skewed analytical results. Inhomogeneous data formats and non-standard data values are additional barriers that can cause problems in the ETL process.

Thus, Xi Dai provided several practical strategies to reduce error frequency and increase success rates after delving deeply into the conclusions gained from ordinary ETL application problems. These include extensive data cleaning, validation, and the adoption of security measures, which eventually improve data quality and reliability. According to Xi Dai, reliable decision-making support for corporations is only possible from data that is both accurate and consistent.

Her viewpoint aligns nicely with the thoughts of Bill Inmon, another influential figure in the data integration sphere. Inmon advocates for a specific approach whereby the data warehouse is scheme-divided into individual data marts to meet the unique data requirements of various business sectors and users, thereby affording more flexible data access and analysis capabilities.

Xi Dai, in her practical work, employs Inmon’s philosophy, coupling it with ETL and data integration practices to offer more robust data integration analytical solutions. Her inventive solutions for ETL workflow methods based on this philosophy have greatly increased data integration efficiency and ensured timely data availability, earning Xi Dai high praise from peers.

There is a corporate and social need for more attention to data quality and security. The insights from notable data engineers such as Xi Dai provide a new perspective: data and its underlying ETL processing have emerged as critical accelerators for both corporate and societal transformation.

In the ever-changing world of data, we need data engineers like Xi Dai. Their experience enables them to empower society through technology by providing robust and consistent data assistance to organizations, while also enlightening our view of the future of data-driven development and motivating greater standards and innovation in the ETL domain.

As time goes by, our relationships with data will only deepen, bringing with it a slew of new issues in terms of data quality and security. This is where we should focus our attention. With dedicated data engineers like Xi Dai leading the way, we remain optimistic about the data industry’s bright and expansive future.

We are barely scraping the surface of what data has to offer us. As we prepare for the future, let us work together, guided by data, to see the revolutionary impact of each technological leap forward.

(By Yipeng Yang)

Media Contact
Company Name: Global News Online
Contact Person: Media Relations
Email: Send Email
City: NY
Country: United States
Website: www.globalnewsonline.info

Alta Dental Solution Adds Dental Lab Materials to Its Online Dental Shop

Alta Dental Solution announced the addition of dental lab materials to its online dental shop for clients to buy dental products with a few clicks.

New York, USA – May 7, 2024 – Alta Dental Solution, a global supplier of dental products and solutions, announced the addition of dental lab materials to its online dental shop, providing dentists and dental professionals with an easy and convenient way to purchase top-quality dental products with just a few clicks.

Dental offices are getting busier as people pay more attention to dental health, resulting in dental consumables being used very quickly. At the same time, dentists and dental clinics are also looking for more high-quality and cost-effective dental products. For these reasons, Alta Dental Solution uses its extensive knowledge in sourcing to bring dentists top-quality dental supplies. To simplify the process of getting dental supplies and instruments, Alta Dental Solutions has created a user-friendly online platform that offers a wide range of dental products and equipment from leading brands. From cosmetic dentistry materials to dental instruments, customers can now find everything they need in one place and have their orders delivered to their doorstep.

“Our goal at Alta Dental Solution is to make it as simple as possible for our clients to access the dental products and equipment they require to provide the best possible care for their patients,” said the team at Alta Dental Solution. “By introducing our dental lab products, we are making it easier than ever for dentists and dental professionals to order the supplies they need at the click of a button.”

In addition to dental lab materials, Alta Dental Solution’s online dental shop also offers cassettes, crowns and bridges, dental equipment and instruments, handpieces and motors. Moreover, Alta Dental Solution’s knowledgeable customer service team is available to assist clients with any questions or concerns they may have about their purchases.

“We understand the importance of efficient and reliable service, which is why we continuously expand the range of our dental supplies to provide a one-stop and seamless shopping experience for our clients,” added the team at Alta Dental Solution. “Whether you are looking to restock on essential dental supplies or upgrade your equipment, we invite you to explore our online shop and discover the convenience of shopping with Alta Dental Solution.”

To learn more about Alta Dental Solution’s online dental shop and start shopping for dental products and equipment today, please kindly visit www.altadentalsolution.com.

About Alta Dental Solution

Alta Dental Solution is a global supplier of dental products and solutions. The company provides a variety of high-quality dental products and equipment as well as OEM/ODM services to meet the different needs of customers. Focusing on the corporate purpose of “Customer Foremost, Quality First”, Alta Dental Solution consistently optimizes and integrates the entire value chain system, striving to create greater value for customers and cooperative suppliers.

Media Contact
Company Name: Alta Dental Solution
Contact Person: Doris Lee
Email: Send Email
Country: United States
Website: https://www.altadentalsolution.com

Schizophrenia Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Otsuka Pharma, Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Schizophrenia pipeline constitutes 70+ key companies continuously working towards developing 70+ Schizophrenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Schizophrenia Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Schizophrenia Market.

 

The Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Schizophrenia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Schizophrenia treatment therapies with a considerable amount of success over the years. 

  • Schizophrenia companies working in the treatment market are Midatech, Addex Therapeutics, Autifony Therapeutics, MapLight Therapeutics, Cyclerion Therapeutics, Valentech LLC, Roche, Merck Sharp & Dohme, Cerevel Therapeutics, Boehringer Ingelheim, Sunovion Pharmaceuticals, Karuna Therapeutics, and others, are developing therapies for the Schizophrenia treatment 

  • Emerging Schizophrenia therapies such as – MTD211, M4 PAM, Back up modulators, ML-007, CY 6463, VLT-015, Ralmitaront, MK-8189, Emraclidine, Iclepertin, Ulotaront, KarXT, and others are expected to have a significant impact on the Schizophrenia market in the coming years. 

  • In August 2023, Sumitomo Pharma revealed disappointing results as two Phase III trials targeting schizophrenia failed to achieve their primary goals. These trials, named DIAMOND 1 and DIAMOND 2, assessed ulotaront’s efficacy in managing acute psychosis among adults diagnosed with schizophrenia. Ulotaront, possessing trace amine-associated receptor 1 (TAAR1) agonist properties alongside 5-HT1A agonist activity, was the focus of investigation. Notably, Otsuka Pharmaceutical collaborates with Sumitomo Pharma in the co-development of this drug candidate.

  • In March 2023, Positive topline results from the Phase 3 EMERGENT-3 trial, which examined the effectiveness, safety, and tolerability of KarXT (xanomeline-trospium), the company’s flagship experimental medication, in adults with schizophrenia, were released by Karuna Therapeutics

 

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder characterized by disruptions in thought processes, perceptions, emotions, and behavior. People with schizophrenia may experience hallucinations (seeing or hearing things that others do not), delusions (false beliefs), disorganized thinking and speech, reduced expression of emotions, and social withdrawal.

 

Get a Free Sample PDF Report to know more about Schizophrenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight

 

Emerging Schizophrenia Drugs Under Different Phases of Clinical Development Include:

  • MTD211: Midatech

  • M4 PAM: Addex Therapeutics

  • Back up modulators: Autifony Therapeutics

  • ML-007: MapLight Therapeutics

  • Luvadaxistat: Takeda

  • CY6463: Cyclerion Therapeutics

  • AVP 786: Avanir Pharmaceuticals

  • CY 6463: Cyclerion Therapeutics

  • VLT-015: Valentech LLC

  • Ralmitaront: Roche

  • MK-8189: Merck Sharp & Dohme

  • Emraclidine: Cerevel Therapeutics

  • Iclepertin: Boehringer Ingelheim

  • Ulotaront: Sunovion Pharmaceuticals

  • KarXT: Karuna Therapeutics

 

Route of Administration

Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • NA

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

 

Schizophrenia Pipeline Therapeutics Assessment

  • Schizophrenia Assessment by Product Type

  • Schizophrenia By Stage and Product Type

  • Schizophrenia Assessment by Route of Administration

  • Schizophrenia By Stage and Route of Administration

  • Schizophrenia Assessment by Molecule Type

  • Schizophrenia by Stage and Molecule Type

 

DelveInsight’s Schizophrenia Report covers around 70+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Schizophrenia product details are provided in the report. Download the Schizophrenia pipeline report to learn more about the emerging Schizophrenia therapies

 

Some of the key companies in the Schizophrenia Therapeutics Market include:

Key companies developing therapies for Schizophrenia are – Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, Boehringer Ingelheim, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Alkermes, Inc. , Solvay Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc, Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc, Amneal Pharmaceuticals, LLC, Recognify Life Sciences, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen, LP, Delpor, Inc., Jiangsu Hansoh Pharmaceutical, Cerevel Therapeutics, LLC, Zogenix, Inc., Luye Pharma, Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, Autifony Therapeutics, Neumora Therapeutics, Adex Therapeutics, and others.

 

Schizophrenia Pipeline Analysis:

The Schizophrenia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Schizophrenia with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia Treatment.

  • Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Schizophrenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Schizophrenia drugs and therapies

 

Schizophrenia Pipeline Market Drivers

  • Emergence of second and third generation anti-phsychotics, increasing need for better and effective treatment are some of the important factors that are fueling the Schizophrenia Market.

 

Schizophrenia Pipeline Market Barriers

  • However, lack of understanding of disease etiology and pathophysiology, patent expiry of major drugs and other factors are creating obstacles in the Schizophrenia Market growth.

 

Scope of Schizophrenia Pipeline Drug Insight    

  • Coverage: Global

  • Key Schizophrenia Companies: Midatech, Addex Therapeutics, Autifony Therapeutics, MapLight Therapeutics, Cyclerion Therapeutics, Valentech LLC, Roche, Merck Sharp & Dohme, Cerevel Therapeutics, Boehringer Ingelheim, Sunovion Pharmaceuticals, Karuna Therapeutics, and others

  • Key Schizophrenia Therapies: MTD211, M4 PAM, Back up modulators, ML-007, CY 6463, VLT-015, Ralmitaront, MK-8189, Emraclidine, Iclepertin, Ulotaront, KarXT, and others

  • Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies

  • Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers 

 

Request for Sample PDF Report for Schizophrenia Pipeline Assessment and clinical trials

 

Table of Contents

1

Schizophrenia Report Introduction

2

Schizophrenia Executive Summary

3

Schizophrenia Overview

4

Schizophrenia- Analytical Perspective In-depth Commercial Assessment

5

Schizophrenia Pipeline Therapeutics

6

Schizophrenia Late Stage Products (Phase II/III)

7

Schizophrenia Mid Stage Products (Phase II)

8

Schizophrenia Early Stage Products (Phase I)

9

Schizophrenia Preclinical Stage Products

10

Schizophrenia Therapeutics Assessment

11

Schizophrenia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Schizophrenia Key Companies

14

Schizophrenia Key Products

15

Schizophrenia Unmet Needs

16 

Schizophrenia Market Drivers and Barriers

17

Schizophrenia Future Perspectives and Conclusion

18

Schizophrenia Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Otsuka Pharma, Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda

Liang’an Xu, Virtual Reality Technology Expert from China: Creating a New Universe Landscape with VR Technology

In 2021, a piece of news caused a sensation on the Internet, mainly about Facebook’s announcement to change its name to Meta, and the concept of metaverse caused a heated discussion all around the world. As the core technology supporting the metaverse, virtual reality (VR) has received unprecedented attention. This technology, which is currently at the forefront of digital technology, is an important sign that human technological level has entered a new stage, and it also embodies humanity’s infinite longing for future life.

At the application level, virtual reality technology has now expanded to multiple fields, from game and entertainment to film and animation, from education and training to medical health… gradually penetrating into all aspects of life, bringing us unprecedented convenience experience. While virtual reality technology shows great application potential and broad prospects, its technical difficulty and complexity also put forward extremely strict requirements on the professionalism and innovation ability of practitioners. In this context, virtual reality technology talents have not only become the key force to promote the continuous progress and breakthrough of virtual reality technology, but also the core engine to lead the entire industry to the peak of innovation and create a new situation.

Mr. Liang’an Xu, an expert in virtual reality technology from China, is undoubtedly one of the outstanding representatives in this field. He has worked in several well-known companies such as UBI Soft Entertainment, Pearl Digital Entertainment, and Hola Games. Through in-depth research on virtual reality technology, he has provided strong technical support for industries such as game development and film production. With extraordinary ability, he joined Epic Games in 2018, an American star game company and the world’s No.1 virtual reality technology company, responsible for providing Unreal Engine-based full-chain technology solutions for enterprise users in various industries in China.

Mr. Liang’an Xu, an expert in virtual reality technology

Over the years, Liang’an Xu has always adhered to the persistent pursuit of technological innovation. He is well aware that the development of virtual reality technology will directly determine the future lifestyle of human beings. Therefore, for every task, he demands himself with the highest standards, and strives to maximize the potential and value of virtual reality technology. In his work, he conducts in-depth research on modeling and graphics rendering technology, and constructs a more delicate and realistic virtual scene by continuously optimizing key links such as lighting models, texture mapping, and shadow processing. At the same time, he is also adept at designing a variety of interaction methods, so that users can obtain a better immersive experience in the virtual world. In order to strive for excellence, he pays special attention to the processing of scene details, and makes the virtual environment more vivid by carefully adjusting elements such as materials, light and shadow, and sound effects. These technical polishes have penetrated into his thinking, making him an absolute technical authority in this field.

As a brave pioneer, Liang’an Xu is not satisfied with the achievements of the work itself. He always pays attention to the development of the industry, and constantly innovates technology according to the needs and pain points of practitioners. Multiple technological achievements independently developed by him, such as Game Architecture Intelligent Auxiliary Platform Based on Multi-objective Optimization Algorithm, Liang’an No. 1 VR Development Intelligent Service System, Digital Human Development and Testing Integrated Cloud Platform, and Intelligent Software for Game and Film Visual Effects Production, have not only fully demonstrated his profound technical foundation and extraordinary innovation ability, but also have brought subversive changes to the rapid development and wide application of virtual reality technology.

Among them, Liang’an No. 1 VR Development Intelligent Service System is his most representative software, which has opened up a new path for the development and application of VR technology with its powerful functions. This software can provide developers with a one-stop VR development solution. Whether you are a beginner or an experienced developer, you can find suitable development tools and resources. Based on the core function of intelligent analysis, the system can monitor all the data in the development process in real time, thus providing accurate optimization suggestions, so that developers can find and solve problems in time. At the same time, it also supports real-time rendering and preview functions, so that developers can view and adjust the visual effects in real time during the work process, and ensure that the final VR application can present the best effect. In addition, the system also has a rich material library and templates. Developers can quickly build delicate and realistic scenes, vivid and flexible character models according to their own needs, thereby greatly improving development efficiency and enabling more creativity and ideas to be quickly realized. It can be said that the emergence of this software has made the entire virtual reality industry take a solid step forward.

As a researcher and leader of virtual reality technology, Liang’an Xu is also well aware of the importance of knowledge sharing and dissemination while continuing to explore cutting-edge technologies. Therefore, he carefully produced more than 50 teaching videos in his spare time and uploaded them to various major video websites. At present, the cumulative number of views of these videos has reached hundreds of thousands. Among them, the content on real-time rendering principles and material application has provided unprecedented help for practitioners to master the core knowledge and application skills of virtual reality technology, and has attracted unanimous praise from the majority of peers once it was launched.

In addition, Liang’an Xu has also actively participated in various industry activities. By giving speeches and serving as judges of competitions, he has not only better promoted and popularized the cutting-edge technology of virtual reality, but also has excavated many outstanding talents and scientific and technological achievements in this field. It is through such efforts that Liang’an Xu has laid a solid foundation for the long-term development of the entire virtual reality industry.

Liang’an Xu himself says that in the future, he will continue to deepen the field of virtual reality technology, continue to explore and try new technologies and applications, create a new “VR Universe”, and provide technical support for more users around the world. It is believed that under the guidance of a group of technical experts represented by Mr. Liang’an Xu who are at the forefront of industry development, virtual reality technology will continue to make new breakthroughs and bring more surprises to the progress of human science and technology.

(Reporter: Nancy Wang)

Media Contact
Company Name: Globalnewsonline
Contact Person: Luayy Alkilani
Email: Send Email
Country: United States
Website: http://www.globalnewsonline.info/

Adam and Ava Trade Places by Betty Collier is Recognized as a Finalist in International Book Awards Contest

Filled with valuable lessons for both children and adults alike, Betty Collier’s Adam and Ava Trade Places is an empowering children’s picture book that promotes honesty, self-awareness and good morals. The book was recognized for its outstanding writing, design and overall market appeal out of thousands of books submitted into the Book Excellence Awards.

Betty Collier is a 9x bestselling, 7x award-winning author. She writes with a passion and purpose—to bring honor and glory to God.Betty writes inspirational non-fiction, Christian fiction, and children’s books that teach life lessons through the eyes of six-year-old twins, Adam and Ava.

A gifted storyteller, Betty is known for captivating readers right from the start, holding their attention with magnetic characters that go through deep, emotional journeys. Readers will find themselves inspired, hoping for the best, and dreaming about the characters as if they were members of their own family.On a personal note, Betty is married to William Collier, the absolute love of her life, whom she first met in middle school. They are the proud parents of two sons and a daughter-in-love, all of whom reside in Shelby County, TN.

This one-on-one interview shares Betty’s background and experience writing Adam and Ava Trade Places.

Tell us about Adam and Ava Trade Places.

Six-year-old Ava’s silly question to her twin brother, Adam, reveals a not-so-well thought out plan: “Adam, wouldn’t it be fun to trade places and trick Mommy?

How can a boy and girl swap places and expect things not to go badly?

Join Adam and Ava in an exciting adventure at school as they discover what happens when they pretend to be someone they are not.

Beautifully illustrated by Cassandra Harris with valuable life lessons for both children and adults, the book highlights that no matter how hard kids try to be something they’re not, their parents always know them for who they truly are. It’s about children discovering their true selves and what lies within them. It’s a priceless lesson even adults need to ponder.

What inspired you to write Adam and Ava Trade Places?

Today, children are inundated with misinformation meant to distract them and spread untruths. I created this book series to be a safe place for children to enjoy the innocence of childhood, while tackling hot topics they are constantly being bombarded with.

While this book’s sensitive subject matter may not be the easiest to discuss, I was inspired to write it from the perspective of two first graders, so kids could relate to the underlying message while still being entertained and enlightened with my gift of storytelling.

I hope this book, as with the others in the Adam and Ava series, acts as a source of encouragement parents can use to discuss sensitive topics and help their children learn and grow. At the end of the day, there is only one truth, and my desire is for this book to empower both children and adults to discover that truth.

How did you feel when you found out you received a Book Excellence Award?

I was absolutely thrilled! Adam and Ava Trade Places was the first children’s book I wrote, so although I’ve received numerous awards for my adult books, being recognized in this genre exceeded my wildest expectations.

Receiving a Book Excellence Award not only validated what I hoped to accomplish with this book, it has also opened doors for me to share the message of the book on a wider scale, with an even larger audience.

How did your background and experience influence your writing?

I tell people that I am a nurse by profession, author by passion, and storyteller by the grace of God.

I first began writing inspirational nonfiction adult books in 2009, which is the basis for crossing over to children’s inspirational books. I discovered with my adult books that if my goal is to inspire and encourage readers, I can do that whether the book is nonfiction or fiction.There is something so magical about creating a fictional story that is so believable that readers get to know the characters on a personal level, as if they are part of their own family. I’ve been able to crossover from adult books to children’s books using that same logic, but on a level children can understand and appreciate as well.

What is one message you would like readers to remember?

My goal is to help children, as well as adults, tackle hot topics in a responsible manner based on truth, values, honor, and morals—attributes that seem to be sorely lacking in our world today.

Ultimately, the key takeaway is simple and can be likened to a very popular bible verse, Proverbs 22:6. “Train up a child in the way he should go: and when he is old, he will not depart from it.”

Purchasing the Book

Adam and Ava Trade Places has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Book Excellence writes, “An original story with a powerful message, Adam and Ava Trade Places follows two inquisitive first graders on a relatable adventure at school. Filled with valuable morals and life lessons, the book is sure to delight and entertain.” In addition, Reader’s Favorite writes, “This book should be available in libraries, schools, and on kids’ bookshelves to be read over and again.

The book is available for sale on Amazon, Barnes & Noble, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/dp/B0CQPC56W3

Readers, parents, educators and book clubs are encouraged to visit Betty’s website to receive updates on author visits and new book releases: https://www.adamandavabooks.com/. You can also connect with her on social media on Facebook, Instagram and YouTube.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adam and Ava Trade Places by Betty Collier is Recognized as a Finalist in International Book Awards Contest

Attention Deficit Hyperactivity Disorder Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Otsuka Pharma, ABVC BioPharma

The Attention Deficit Hyperactivity Disorder Market Forecast report offers an in-depth understanding of the Attention Deficit Hyperactivity Disorder, historical and forecasted epidemiology as well as the Attention Deficit Hyperactivity Disorder market trends in the 7MM.

DelveInsight’s “Attention Deficit Hyperactivity Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Attention Deficit Hyperactivity Disorder, historical and forecasted epidemiology as well as the Attention Deficit Hyperactivity Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Attention Deficit Hyperactivity Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Attention Deficit Hyperactivity Disorder Market Forecast

 

Some of the key facts of the Attention Deficit Hyperactivity Disorder Market Report: 

  • The Attention Deficit Hyperactivity Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In March 2023, Cingulate and Indegene have entered into a collaborative commercialization agreement aimed at offering commercial assistance for Cingulate’s primary candidate CTx-1301 (dexmethylphenidate) intended for attention-deficit/hyperactivity disorder (ADHD), once endorsed by the US Food and Drug Administration (FDA). This partnership encompasses comprehensive services across various functions, employing an omnichannel marketing strategy tailored specifically to oversee pre-commercial support during Cingulate’s Phase 3 clinical trials and to efficiently introduce CTx-1301 nationwide upon potential FDA approval.

  • In February 2023, Pharmanovia has broadened its neurology offerings with a fresh licensing deal with Axsome Therapeutics, Inc., headquartered in the US. Under this agreement, Pharmanovia secures exclusive marketing privileges for Sunosi (solriamfetol) and gains the opportunity to investigate solriamfetol’s potential in additional neurological disorders, including attention deficit hyperactivity disorder (ADHD).

  • In February 2023, Cingulate reported encouraging initial findings from the CTx-1301-003 study, evaluating the impact of food on the absorption of its primary candidate CTx-1301. CTx-1301, an innovative, investigational extended-release tablet formulation of dexmethylphenidate, an FDA-approved compound for attention deficit/hyperactivity disorder (ADHD) treatment, was the subject of the trial. Results indicated that CTx-1301 can be administered with or without food. The study included multiple pharmacokinetic (PK) assessments, and observed adverse events were consistent with prior observations, suggesting a favorable tolerability profile.

  • In January 2023, NLS Pharmaceutics Ltd. disclosed that the Patents Registry of the Intellectual Property Department in The Government of the Hong Kong Special Administrative Region has approved Patent Application 42022055879.5. This patent pertains to the utilization of Mazindol ER for the treatment of ADHD and is projected to remain valid until at least 2037.

  • In January 2023, ABVC BioPharma, Inc. revealed that Dr. Keith McBurnett, a Psychiatry Professor at the University of California San Francisco, presented findings from the Phase IIa investigation of its medical intervention, ABV-1505 ADHD, on January 14, 2023, at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session. The Phase IIa study utilized the active pharmaceutical ingredient PDC-1421, contained in ABV-1505, involving six adult subjects with confirmed ADHD. Results indicated that both low and high doses of PDC-1421 were safe, well-tolerated, and effective throughout the treatment and subsequent follow-up period.

  • According to the ADHD Institute, a global average prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (under 18 years old) is estimated at 2.2%, with a range from 0.1% to 8.1%.

  • In a research study led by Riedel et al. (2021), the age- and sex-standardized prevalence of Attention Deficit Hyperactivity Disorder (ADHD) varied between 37.2 per 1,000 individuals in 2009 and 43.5 per 1,000 individuals in 2015, encompassing all the data years examined.

  • Key Attention Deficit Hyperactivity Disorder Companies: Otsuka Pharmaceuticals, ABVC BioPharma, Inc, Cingulate Therapeutics, GlaxoSmithKline, New River Pharmaceuticals, DSM Nutritional Products, Inc., Mind Medicine, Inc., Materia Medica Holding, Arbor Pharmaceuticals, Inc., Pfizer, Tris Pharma, Inc., Janssen Korea, Ltd., Korea, Janssen Pharmaceutical K.K., and others

  • Key Attention Deficit Hyperactivity Disorder Therapies: Centanafadine, ABV-1505, CTx-1301, Extended-release bupropion hydrochloride, Vyvanse (lisdexamfetamine dimesylate), NRP104, DHA Omega-3, MM-120, Prospecta, Amphetamine Sulfate, Quillivant Oral Suspension XR, TRI102, OROS Methylphenidate HCL, JNS001, and others

  • The Attention Deficit Hyperactivity Disorder epidemiology based on gender analyzed that ADHD diagnosis by a physician or psychologist is significantly more prevalent for boys (7.9%) than for girls (1.8%).

  • The Attention Deficit Hyperactivity Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Attention Deficit Hyperactivity Disorder pipeline products will significantly revolutionize the Attention Deficit Hyperactivity Disorder market dynamics.

 

Attention Deficit Hyperactivity Disorder Overview

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that commonly affects children but can persist into adulthood. It is characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that interferes with daily functioning and development.

 

Get a Free sample for the Attention Deficit Hyperactivity Disorder Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market

 

Attention Deficit Hyperactivity Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Attention Deficit Hyperactivity Disorder Epidemiology Segmentation:

The Attention Deficit Hyperactivity Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Attention Deficit Hyperactivity Disorder

  • Prevalent Cases of Attention Deficit Hyperactivity Disorder by severity

  • Gender-specific Prevalence of Attention Deficit Hyperactivity Disorder

  • Diagnosed Cases of Episodic and Chronic Attention Deficit Hyperactivity Disorder

 

Download the report to understand which factors are driving Attention Deficit Hyperactivity Disorder epidemiology trends @ Attention Deficit Hyperactivity Disorder Epidemiology Forecast

 

Attention Deficit Hyperactivity Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Attention Deficit Hyperactivity Disorder market or expected to get launched during the study period. The analysis covers Attention Deficit Hyperactivity Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Attention Deficit Hyperactivity Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Attention Deficit Hyperactivity Disorder Therapies and Key Companies

  • Centanafadine: Otsuka Pharmaceuticals

  • ABV-1505: ABVC BioPharma, Inc

  • CTx-1301: Cingulate Therapeutics

  • Extended-release bupropion hydrochloride: GlaxoSmithKline

  • Vyvanse (lisdexamfetamine dimesylate), NRP104: New River Pharmaceuticals

  • DHA Omega-3: DSM Nutritional Products, Inc.

  • MM-120: Mind Medicine, Inc.

  • Prospecta: Materia Medica Holding

  • Amphetamine Sulfate: Arbor Pharmaceuticals, Inc.

  • Quillivant Oral Suspension XR: Pfizer

  • TRI102: Tris Pharma, Inc.

  • OROS Methylphenidate HCl: Janssen Korea, Ltd., Korea

  • JNS001: Janssen Pharmaceutical K.K.

 

Discover more about therapies set to grab major Attention Deficit Hyperactivity Disorder market share @ Attention Deficit Hyperactivity Disorder Treatment Landscape

 

Scope of the Attention Deficit Hyperactivity Disorder Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Attention Deficit Hyperactivity Disorder Companies: Otsuka Pharmaceuticals, ABVC BioPharma, Inc, Cingulate Therapeutics, GlaxoSmithKline, New River Pharmaceuticals, DSM Nutritional Products, Inc., Mind Medicine, Inc., Materia Medica Holding, Arbor Pharmaceuticals, Inc., Pfizer, Tris Pharma, Inc., Janssen Korea, Ltd., Korea, Janssen Pharmaceutical K.K., and others

  • Key Attention Deficit Hyperactivity Disorder Therapies: Centanafadine, ABV-1505, CTx-1301, Extended-release bupropion hydrochloride, Vyvanse (lisdexamfetamine dimesylate), NRP104, DHA Omega-3, MM-120, Prospecta, Amphetamine Sulfate, Quillivant Oral Suspension XR, TRI102, OROS Methylphenidate HCL, JNS001, and others

  • Attention Deficit Hyperactivity Disorder Therapeutic Assessment: Attention Deficit Hyperactivity Disorder current marketed and Attention Deficit Hyperactivity Disorder emerging therapies

  • Attention Deficit Hyperactivity Disorder Market Dynamics: Attention Deficit Hyperactivity Disorder market drivers and Attention Deficit Hyperactivity Disorder market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Attention Deficit Hyperactivity Disorder Unmet Needs, KOL’s views, Analyst’s views, Attention Deficit Hyperactivity Disorder Market Access and Reimbursement 

 

To know more about Attention Deficit Hyperactivity Disorder companies working in the treatment market, visit @ Attention Deficit Hyperactivity Disorder Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Attention Deficit Hyperactivity Disorder Market Report Introduction

2. Executive Summary for Attention Deficit Hyperactivity Disorder

3. SWOT analysis of Attention Deficit Hyperactivity Disorder

4. Attention Deficit Hyperactivity Disorder Patient Share (%) Overview at a Glance

5. Attention Deficit Hyperactivity Disorder Market Overview at a Glance

6. Attention Deficit Hyperactivity Disorder Disease Background and Overview

7. Attention Deficit Hyperactivity Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Attention Deficit Hyperactivity Disorder 

9. Attention Deficit Hyperactivity Disorder Current Treatment and Medical Practices

10. Attention Deficit Hyperactivity Disorder Unmet Needs

11. Attention Deficit Hyperactivity Disorder Emerging Therapies

12. Attention Deficit Hyperactivity Disorder Market Outlook

13. Country-Wise Attention Deficit Hyperactivity Disorder Market Analysis (2019–2032)

14. Attention Deficit Hyperactivity Disorder Market Access and Reimbursement of Therapies

15. Attention Deficit Hyperactivity Disorder Market Drivers

16. Attention Deficit Hyperactivity Disorder Market Barriers

17.  Attention Deficit Hyperactivity Disorder Appendix

18. Attention Deficit Hyperactivity Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Attention Deficit Hyperactivity Disorder Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Otsuka Pharma, ABVC BioPharma

Diabetic Peripheral Neuropathy Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Regenacy Pharma

The Diabetic Peripheral Neuropathy Market Forecast report offers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the 7MM.

The Diabetic Peripheral Neuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Peripheral Neuropathy pipeline products will significantly revolutionize the Diabetic Peripheral Neuropathy market dynamics.  

 

DelveInsight’s “Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Diabetic Peripheral Neuropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Diabetic Peripheral Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Peripheral Neuropathy Market Insights

 

Some of the key facts of the Diabetic Peripheral Neuropathy Market Report: 

  • The Diabetic Peripheral Neuropathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • The estimated number of cases of painful peripheral neuropathy in the United States is expected to increase steadily at a compound annual growth rate (CAGR) of 4.6% during the study duration spanning from 2020 to 2034.

  • In December 2023, Vertex Pharmaceuticals revealed encouraging outcomes from its Phase II trial assessing the effectiveness of VX-548, a specific inhibitor targeting NaV1.8, in individuals suffering from painful diabetic peripheral neuropathy (DPN). Administering VX-548 resulted in a notable and meaningful decrease in the Numeric Pain Rating Scale (NPRS) from baseline, a primary measure, demonstrating both statistical significance and clinical relevance. Furthermore, the treatment exhibited good tolerability across all dosage levels examined during the study.

  • In 2023, the combined prevalent instances of diabetic peripheral neuropathy in the Seven Major Markets (7MM) amounted to approximately 34 million cases, with the United States exhibiting the highest prevalence of this condition.

  • By 2023, the greatest number of type-specific instances of diabetic neuropathy, particularly peripheral diabetic neuropathy, were noted in the Seven Major Markets (7MM). This trend is expected to potentially rise by 2034.

  • In 2023, the United States represented nearly half of all treated cases, a proportion anticipated to rise by 2034.

  • Bodman and Varacello (2023) reported that individuals diagnosed promptly with Type 1 diabetes mellitus can lower the likelihood of developing diabetic peripheral neuropathy by 78% through stringent glucose management. Conversely, for those diagnosed later with prolonged hyperglycemia or Type 2 diabetes, tight glucose control only offers a risk reduction ranging from 5% to 9%. 

  • Key Diabetic Peripheral Neuropathy Companies: Helixmith, Vertex Pharmaceuticals, Astrazeneca, Eli Lilly and Company, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eva Pharma, GlaxoSmithKline, and others

  • Key Diabetic Peripheral Neuropathy Therapies: ENGENSIS (VM202), VX-548, MEDI7352, LY3556050, pregabalin sustained-release tablets, RTA 901, LX9211 (blinded), JMKX000623, Alpha-Lipoic Acid (ALA), GSK3858279, and others

  • The Diabetic Peripheral Neuropathy epidemiology based on gender analyzed that the prevalence of Diabetic Peripheral Neuropathy increases significantly with age

 

Diabetic Peripheral Neuropathy Overview

Diabetic Peripheral Neuropathy (DPN) is a type of nerve damage that occurs as a complication of diabetes mellitus. It affects the peripheral nerves, which are the nerves outside the brain and spinal cord that connect the rest of the body to the central nervous system.

 

Get a Free sample for the Diabetic Peripheral Neuropathy Market Report:

https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market

 

Diabetic Peripheral Neuropathy Market  

The dynamics of the Diabetic Peripheral Neuropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

 

Diabetic Peripheral Neuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Diabetic Peripheral Neuropathy Epidemiology Segmentation:

The Diabetic Peripheral Neuropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Diabetic Peripheral Neuropathy

  • Prevalent Cases of Diabetic Peripheral Neuropathy by severity

  • Gender-specific Prevalence of Diabetic Peripheral Neuropathy

  • Diagnosed Cases of Episodic and Chronic Diabetic Peripheral Neuropathy

 

Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends @ Diabetic Peripheral Neuropathy Epidemiological Insights

 

Diabetic Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Peripheral Neuropathy market or expected to get launched during the study period. The analysis covers Diabetic Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Peripheral Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Diabetic Peripheral Neuropathy treatment, visit @ Diabetic Peripheral Neuropathy Medications

 

Diabetic Peripheral Neuropathy Therapies and Key Companies

  • ENGENSIS (VM202): Helixmith

  • VX-548: Vertex Pharmaceuticals

  • MEDI7352: Astrazeneca

  • LY3556050: Eli Lilly and Company

  • pregabalin sustained-release tablets: CSPC Ouyi Pharmaceutical

  • RTA 901: Reata

  • LX9211 (blinded): Lexicon Pharmaceuticals

  • JMKX000623: Jemincare

  • Alpha-Lipoic Acid (ALA): Eva Pharma

  • GSK3858279: GlaxoSmithKline

 

Diabetic Peripheral Neuropathy Market Drivers

  • Low-cost off-label medications like gabapentin and tricyclic antidepressants are very effective, presenting patients with numerous treatment options for pain management. 

  • New treatment options like topical 8% capsaicin patch, new electrical stimulation methods are providing patients with safer and effective treatment options. 

 

Diabetic Peripheral Neuropathy Market Unmet Needs

  • Since the current treatment landscape lacks a disease-modifying treatment option and is solely dependent on symptomatic relief, emerging disease-modifying therapies can not only expect to have a high uptake, but they can also charge a significant premium price. 

  • Being very safe and non-addictive, CBD holds promise of becoming an optimal long term treatment option for pain management in the near future.

 

Scope of the Diabetic Peripheral Neuropathy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Diabetic Peripheral Neuropathy Companies: Helixmith, Vertex Pharmaceuticals, Astrazeneca, Eli Lilly and Company, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eva Pharma, GlaxoSmithKline, and others

  • Key Diabetic Peripheral Neuropathy Therapies: ENGENSIS (VM202), VX-548, MEDI7352, LY3556050, pregabalin sustained-release tablets, RTA 901, LX9211 (blinded), JMKX000623, Alpha-Lipoic Acid (ALA), GSK3858279, and others

  • Diabetic Peripheral Neuropathy Therapeutic Assessment: Diabetic Peripheral Neuropathy current marketed and Diabetic Peripheral Neuropathy emerging therapies

  • Diabetic Peripheral Neuropathy Market Dynamics: Diabetic Peripheral Neuropathy market drivers and Diabetic Peripheral Neuropathy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Diabetic Peripheral Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Peripheral Neuropathy Market Access and Reimbursement

 

Discover more about therapies set to grab major Diabetic Peripheral Neuropathy market share @ Diabetic Peripheral Neuropathy market forecast

 

Table of Contents 

1. Diabetic Peripheral Neuropathy Market Report Introduction

2. Executive Summary for Diabetic Peripheral Neuropathy

3. SWOT analysis of Diabetic Peripheral Neuropathy

4. Diabetic Peripheral Neuropathy Patient Share (%) Overview at a Glance

5. Diabetic Peripheral Neuropathy Market Overview at a Glance

6. Diabetic Peripheral Neuropathy Disease Background and Overview

7. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Peripheral Neuropathy 

9. Diabetic Peripheral Neuropathy Current Treatment and Medical Practices

10. Diabetic Peripheral Neuropathy Unmet Needs

11. Diabetic Peripheral Neuropathy Emerging Therapies

12. Diabetic Peripheral Neuropathy Market Outlook

13. Country-Wise Diabetic Peripheral Neuropathy Market Analysis (2020–2034)

14. Diabetic Peripheral Neuropathy Market Access and Reimbursement of Therapies

15. Diabetic Peripheral Neuropathy Market Drivers

16. Diabetic Peripheral Neuropathy Market Barriers

17.  Diabetic Peripheral Neuropathy Appendix

18. Diabetic Peripheral Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Peripheral Neuropathy Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Regenacy Pharma

Indie-Pop Artist Catlea Turns The Tables on an Unfaithful Lover

Indie-Pop Artist Catlea Turns The Tables on an Unfaithful Lover
‘Lying’ is the Second Release Off Upcoming Album

Indie-pop artist, Catlea, releases ‘Lying’, a catchy, uplifting song featuring a contagious, energetic groove and Catlea’s sensual yet powerful vocals. It’s the second release off Language Barrier—Catlea’s upcoming full-length album—following on the heels of the successful debut single “Like Me”, which achieved 1.2 million streams across all platforms and 150,000 music video streams on YouTube.

‘Lying’ turns the tables on an unfaithful lover, saying I won’t do what you did—lie and cheat—but if I did, I would be happier because the love of a close friend is better than the lies of a gaslighting partner.

“Lying” is supported by a robust social media campaign on Instagram, Facebook, Twitter, and a 42-show US Midwest tour, and PR from a professional promotional firm.

Since their first song in mid-2019, Catlea has:

  • Released 11 international singles produced in LA, New York, Chicago, London, Barcelona, and Bucharest
  • Achieved 6 million streams
  • Gathered 140,000 followers on social media and streaming services
  • Garnered 890,000 YouTube views

The singer-songwriter and multi-instrumentalist from Cincinnati, Ohio spent three years writing, producing, and perfecting ten new alt-indie songs for a full-length album called Language Barrier, working closely with producer Jason Boshoff (Ed Sheeran, Josh Groban, David Gray, Rufus Wainwright) of Room to Studios in Barcelona, Spain. All Catlea vocals were recorded in Cincinnati, Ohio at PLAY Audio (formerly Gwynne Sound).

Special thanks and appreciation to:

  • Jason Boshoff — producer, synths, programming, mixing and mastering*
  • Oscar Garcia-Bragado — guitars, bass*
  • Bryan Curtis — Drums**
  • Drew Marcum (aka Dreweybear) — Vocal Sound Engineer ***
  • Cover art by Catlea, animation by Infinity Focus Media

*Room to Studio, Barcelona, Spain

**Holistic Drums, Barcelona, Spain

***Play Audio Agency, Cincinnati, OH

ABOUT

Singer-songwriter and multi-instrumentalist Catlea’s musical style covers an eclectic spectrum from alt-indie to rock, to pop and EDM. The alt-indie singer’s vocals range from angelic to raw and powerful. Complimenting their distinctive vocals, Catlea plays piano, acoustic guitar, rhythm guitar, and ukulele.

Since their first song in mid-2019, Catlea has:

Released 11 international singles produced in LA, New York, Chicago, London, Barcelona, and Bucharest

▪ Achieved 5.9 million streams

▪ Gathered 140,000 followers on social media and streaming services

▪ Garnered 880,000 YouTube views

LINKS

Facebookhttps://www.facebook.com/CatleaCreates

Instagram: https://www.instagram.com/catleacreates/

Twitterhttps://twitter.com/CatleaCreates

YouTubehttps://www.youtube.com/catlea

Spotify: https://open.spotify.com/artist/3MKB5HGt7ZcprzEZt4BxMV?si=SnfOJRJITE-zDuqadyI_Xg

SoundCloudhttps://soundcloud.com/catlea

Media Contact
Company Name: Warning Shot Records
Contact Person: David Rippe
Email: Send Email
Phone: 513-253-4854
Address:2100 Sinton Ave., #18
City: Cincinnati
State: Ohio
Country: United States
Website: https://www.facebook.com/CatleaCreates

Ramona Baxter’s Fairytales and Street Fights Hits International Bestseller Status

Ramona Baxter’s Fairytales and Street Fights Hits International Bestseller Status

When one truly understands and develops this ability, all things are possible.
Ramona Baxter’s Fairytales and Street Fights: How to Give Your Inner Warrior Wings has become a #1 International Bestseller.

Fairytales and Street Fights: How to Give Your Inner Warrior Wings by Ramona Baxter has achieved #1 International Bestseller status within eight hours of its launch. Her book hit bestseller status in the US and Canada, with a total of thirty-two bestseller categories. Fourteen of these categories ranked #1.

“I am thrilled to announce that my book has achieved International Bestseller status,” Ramona Baxter said. “I was inspired to write my life story when (by the grace of God) my twenty-year addiction to alcohol was lifted because I had committed to give my sister a kidney.

Ramona writes to a reader who is no stranger to intense emotional pain, but is primed for deep personal growth. In her book, Ramona is very open and honest in writing about her experiences. She wants her readers to understand that while pain can be crippling at times, that pain in retrospect, can provide inspiration and solutions.

“I want my readers to find and live their most spectacular version of life,” she added. “No matter how deeply we may have fallen, we each possess the strength to rise again, and forge a path toward healing, compassion, and self-acceptance.”

Ramona teaches that everything begins with the self. The individuals we attract into our lives support the beliefs we hold about ourselves, positive or negative.

She unapologetically sets the stage for an engaging, transformational self-help memoir that expresses the crazy machinations of a closet addict and the astonishing miracle that freed her.

Ramona’s favorite quote is:

“Everything is energy, and that is all there is to it. Match the frequency of the reality you want and you cannot help but get that reality. It can be no other way. This is not philosophy. This is physics.” ~ Albert Einstein

She considers this to be the most profound piece of information humanity has ever received as human beings. When one truly understands and develops this ability, all things are possible.

Ramona offers simple, sound advice for those seeking real change in their lives:

“Self-love is always the answer. It allows us to change any situation that isn’t serving us.”

About The Author:

Ramona Baxter is a writer and speaker renowned for her entrepreneurship and inventive spirit. She possesses an innate curiosity and a passion for change. Having launched three successful businesses, she has always been drawn to the world of innovation. Ramona patented an idea that revolutionized industries. Always rising to any challenge, she also created on-site childcare solutions for single mothers in school.

Social Media Information:

Insta: fairytalesandstreetfights

Facebook Page: Winged Warriors

Media Contact
Contact Person: Ramona Baxter
Email: Send Email
Phone: 760-505-8372
Country: United States
Website: https://www.fairytalesandstreetfights.com/

Quality and Lifecycle Management Software Market Growth, Opportunities Business Scenario, Share, Growth Size, Scope, Key Segments and Forecast to 2027

“Aras (US), Arena Solutions (US), Autodesk (US), Dassault Systemes (France), Oracle (US), Parasoft (US), SAP (Germany), SAS Institute (US), ComplianceQuest (US), Siemens (Germany), PTC (US), Atlassian (Australia), HPE (US), IBM Corporation (US), Microsoft (US), Veeva Systems (US), Intellect (US), Kovair Software (US), Micro Focus (UK), Neudesic (US).”
Quality and Lifecycle Management Software Market by Solution (Quality Management and Bill of Material Management), Deployment Mode, Organization Size, Vertical (Automotive & Transport and Industrial Manufacturing) and Region – Global Forecast to 2027

MarketsandMarkets forecasts the global Quality and Lifecycle Management Software Market size is expected to grow from USD 24.6 billion in 2022 to USD 34.9 billion by 2027, at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period. The presence of a large number of passenger cars has increased the need to improve the driving experience, which is encouraging the use of QLM software.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267190066

Quality management solution segment to hold the largest market size during the forecast period

Quality management software helps organizations to reduce product and operating costs while helping them to improve product quality. Thus, quality management software is necessary to capture various complaints, defects, and non-conformances. Quality management software helps identify, analyze, and share critical product quality data, which helps the design, manufacturing, and quality improvement teams share and analyze their views. The growth is mainly contributed by decreasing complexities and increasing the effectiveness of cloud-based deployments. Additionally, the advancements in security measures in cloud-based databases have further bolstered the demand for hosted solutions. Thus, hosted quality management allows organizations to identify, analyze, and share critical product quality data in a secure environment at any given location. These benefits have necessitated the urgency of hosted quality management solutions for organizations to maintain their competitiveness in their respective industry vertical.

Consumer goods & retail vertical to record the highest CAGR during the forecast period

Competition in consumer goods, such as food, beverages, and apparel, has increased vastly over the past few years. The industry continues to face great production and pricing demand from customers. In addition, there is a constant flow of new entrants in this industry, and the supply chains and product structure are growing increasingly complex. Organizations must also comply with the ever-changing regulations and safety requirements for ingredients, packaging, environment, and more. Moreover, the growth in the retail industry is equally notable. Hence, companies are now using QLM software to control and manage product data and work better with suppliers. Quality and lifecycle software provides them with solutions for formula and recipe management, raw material management, change management, document and data control, quality and regulatory compliance, packaging, labeling, and more. Therefore the adoption of QLM software in the consumer goods industry has been increasing and will continue to do so. This vertical will become one of the major spending industries in this market.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=267190066

Unique Features in the Quality and Lifecycle Management Software Market

QLM software provides end-to-end lifecycle management capabilities that span the whole product lifecycle, including design, development, manufacture, distribution, and servicing, from conception to retirement.

To guarantee adherence to industry norms and laws, QLM solutions incorporate quality management functions including document control, non-conformance management, corrective and preventative actions (CAPA), risk management, and audit management.

Through improved visibility, transparency, and alignment, QLM software facilitates communication and cooperation across cross-functional teams, suppliers, partners, and customers throughout the product lifecycle, enabling collaborative product development.

Through the automation of change management procedures, QLM software enables businesses to monitor, assess, authorise, and carry out modifications to product designs, specifications, paperwork, and procedures while preserving traceability and compliance.

QLM systems come with supplier quality management features that let businesses assess, track, and work together with suppliers to guarantee the dependability and quality of parts, supplies, and services that are acquired.

Major Highlights of the Quality and Lifecycle Management Software Market

In order to improve quality management and lifecycle optimisation, the QLM Software Market is undergoing innovation through the introduction of AI, machine learning, IoT, and predictive analytics capabilities, as well as consolidation through mergers and acquisitions

In order to support data-driven decision-making and process optimisation, advanced analytics and business intelligence capabilities—which offer actionable insights into quality measurements, process performance, supplier performance, and customer feedback—are increasingly becoming crucial components of QLM solutions.

To optimise processes, cut costs, and improve customer satisfaction, organisations are using QLM systems to support continuous improvement efforts like Kaizen, Six Sigma, Lean Manufacturing, and Total Quality Management (TQM).

In order to guarantee product quality and dependability, there is a greater emphasis on supplier quality management and cooperation. QLM systems facilitate performance monitoring, communication, and cooperation throughout the supply chain.

Because of their affordability, scalability, and flexibility, cloud-based QLM solutions are becoming more and more popular. They enable businesses to access complex QLM features without having to make large upfront expenditures in IT infrastructure.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=267190066

These market players have adopted various growth strategies, such as partnerships, acquisitions, agreements, and collaborations, and new product enhancements to expand their presence in the QLM software market. New product launches, product enhancements and collaborations have been the most adopted strategies by major players in past few years, which helped companies to innovate their offerings and broaden their customer base.

Aras Corporation develops and delivers enterprise open-source solutions. The company provides a range of Quality and Lifecycle Management (QLM) software solutions based on an enterprise application framework, a model-based service-oriented architecture built on open web standards for the development of flexible and supportable applications that deploy quickly and adapt easily to evolving business needs. The company also provides consulting services that include pilot, customization, deployment, installation, CAD/ERP applications integration, custom training, data migration, system optimization, and upgrades. Aras Corporation delivers its solutions through license and cloud options. The Aras platform and product lifecycle management applications connect users from all disciplines and functions to critical product data and processes throughout the lifecycle and extended supply chain. The platform is used by Airbus, Audi, Denso, Honda, Kawasaki, Microsoft, Mitsubishi, and Nissan to manage complex change and traceability. The Aras platform is also available as a SaaS offering, which provides the same benefits while allowing organizations to benefit from the cloud’s performance, availability, and scalability.

Arena assists businesses in developing innovative products that change the world. Arena unifies product lifecycle management (PLM) and quality management system (QMS) processes, enabling all stakeholders involved in product development and commercialization to collaborate quickly and effectively. Dispersed teams can use Arena to accelerate the design and delivery of high-quality products. Users can confidently create, control, and collaborate anytime and anywhere with Arena’s product lifecycle management (PLM) and quality management system (QMS) solutions. Currently Arena has been acquired by PTC. Arena is intended to assist modern manufacturers in accelerating product development and bringing innovative products to market as quickly as possible. Arena is designed to protect our customers’ product and quality information at every level of security. We take a risk-based approach and employ industry-standard protocols and mechanisms throughout our solution, from the physical layer to the policies and application layer.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/quality-lifecycle-management-software-market-267190066.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Quality and Lifecycle Management Software Market Growth, Opportunities Business Scenario, Share, Growth Size, Scope, Key Segments and Forecast to 2027